Rekah Pharmaceutical Industry Ltd. (REKA.TA)
ILA 1176.0
(-1.26%)
ILA 1176.0
(-1.26%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 329.13 Million ILS | 14.95% |
| 2022 | 286.33 Million ILS | 8.45% |
| 2021 | 264.02 Million ILS | 3.91% |
| 2020 | 254.09 Million ILS | 19.92% |
| 2019 | 211.89 Million ILS | 41.62% |
| 2018 | 149.62 Million ILS | -0.47% |
| 2017 | 150.32 Million ILS | -30.68% |
| 2016 | 216.86 Million ILS | 8.34% |
| 2015 | 200.16 Million ILS | -14.11% |
| 2014 | 233.05 Million ILS | 4.21% |
| 2013 | 223.64 Million ILS | -1.43% |
| 2012 | 226.9 Million ILS | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 326.1 Million ILS | -0.92% |
| 2024 Q2 | 282.68 Million ILS | -13.32% |
| 2023 Q2 | 333.68 Million ILS | 17.7% |
| 2023 FY | 329.13 Million ILS | 14.95% |
| 2023 Q1 | 283.51 Million ILS | -0.99% |
| 2023 Q4 | 329.13 Million ILS | 4.66% |
| 2023 Q3 | 314.48 Million ILS | -5.76% |
| 2022 FY | 286.33 Million ILS | 8.45% |
| 2022 Q2 | 286.58 Million ILS | 5.04% |
| 2022 Q3 | 278.39 Million ILS | -2.86% |
| 2022 Q4 | 286.33 Million ILS | 2.85% |
| 2022 Q1 | 272.83 Million ILS | 3.34% |
| 2021 FY | 264.02 Million ILS | 3.91% |
| 2021 Q4 | 264.02 Million ILS | -2.96% |
| 2021 Q3 | 272.08 Million ILS | 10.3% |
| 2021 Q1 | 243.59 Million ILS | -4.13% |
| 2021 Q2 | 246.68 Million ILS | 1.27% |
| 2020 Q3 | 255.46 Million ILS | 6.97% |
| 2020 Q1 | 233.97 Million ILS | 10.42% |
| 2020 Q2 | 238.81 Million ILS | 2.07% |
| 2020 Q4 | 254.09 Million ILS | -0.53% |
| 2020 FY | 254.09 Million ILS | 19.92% |
| 2019 Q3 | 194.28 Million ILS | 9.76% |
| 2019 FY | 211.89 Million ILS | 41.62% |
| 2019 Q2 | 177.01 Million ILS | -9.61% |
| 2019 Q1 | 195.82 Million ILS | 30.88% |
| 2019 Q4 | 211.89 Million ILS | 9.06% |
| 2018 Q1 | 177.52 Million ILS | 18.09% |
| 2018 Q4 | 149.62 Million ILS | 0.9% |
| 2018 Q3 | 148.28 Million ILS | -6.33% |
| 2018 Q2 | 158.3 Million ILS | -10.82% |
| 2018 FY | 149.62 Million ILS | -0.47% |
| 2017 Q3 | 206.58 Million ILS | -1.0% |
| 2017 FY | 150.32 Million ILS | -30.68% |
| 2017 Q2 | 208.67 Million ILS | -6.76% |
| 2017 Q1 | 223.8 Million ILS | 3.2% |
| 2017 Q4 | 150.32 Million ILS | -27.23% |
| 2016 Q1 | 215.14 Million ILS | 7.48% |
| 2016 FY | 216.86 Million ILS | 8.34% |
| 2016 Q4 | 216.86 Million ILS | 5.36% |
| 2016 Q3 | 205.83 Million ILS | 1.41% |
| 2016 Q2 | 202.98 Million ILS | -5.65% |
| 2015 FY | 200.16 Million ILS | -14.11% |
| 2015 Q4 | 200.16 Million ILS | 1.45% |
| 2015 Q3 | 197.31 Million ILS | -1.66% |
| 2015 Q2 | 200.64 Million ILS | -11.37% |
| 2015 Q1 | 226.39 Million ILS | -2.86% |
| 2014 Q1 | 249.2 Million ILS | 11.43% |
| 2014 FY | 233.05 Million ILS | 4.21% |
| 2014 Q4 | 233.05 Million ILS | -1.26% |
| 2014 Q3 | 236.03 Million ILS | -0.61% |
| 2014 Q2 | 237.47 Million ILS | -4.71% |
| 2013 Q1 | 217.7 Million ILS | -4.05% |
| 2013 Q3 | 219 Million ILS | -1.09% |
| 2013 FY | 223.64 Million ILS | -1.43% |
| 2013 Q2 | 221.42 Million ILS | 1.71% |
| 2013 Q4 | 223.64 Million ILS | 2.12% |
| 2012 FY | 226.9 Million ILS | 0.0% |
| 2012 Q4 | 226.9 Million ILS | 6.17% |
| 2012 Q3 | 213.71 Million ILS | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Cannabotech LTD | 9.68 Million ILA | -3297.708% |